Dylan Dupuis, Ph.D.

Managing Director, Senior Research Analyst



Dylan Dupuis, Ph.D., is a Managing Director, Senior Research Analyst at ROTH MKM, specializing in biotechnology. Dr. Dupuis brings both buy-side and sell-side experience, having joined ROTH MKM from Altium Capital, a healthcare focused LIS hedge fund where he served as a SMID-cap Biotech Analyst. He also gained experience at SVB Leerink, where he worked for two years and was promoted to VP Equity Research, Senior Associate, focusing on immunology, inflammatory, and metabolic diseases. Additionally, he served as a Research Associate at B. Riley FBR, covering SMID-cap Biotech, and worked as a trader and assistant branch manager at Seven Points Capital, LLC.

Dr. Dupuis holds a B.S. in Biology and Chemistry from Lycoming College and obtained his Ph.D. in Molecular Biology from Lehigh University, with a research focus on A-to-I RNA editing. He further expanded his expertise through a Post-Doctoral Research Fellowship at the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center, Harvard Medical School.


Joined Roth

February 2023

Sector Focus



B.S. from Lycoming College; Ph.D. from Lehigh University


Altium Capital; SVB Leerink; B. Riley FBR; Sevenpoints Capital; Beth Israel Deaconess Medical Center